(Reuters) -The U.S. Food and Drug Administration on Friday approved Krystal Biotech Inc's first-of-its kind topical gene therapy for patients with a genetic skin disorder, sending its shares up 7% in ...

Earnings call Crystal Biotech reported Q2 2025 revenue of $96M, up 9% sequentially, driven by patient restarts and early salesforce expansion. EPS came in at $1.29 diluted, marking two years of ...

CEO Krish Krishnan highlighted Krystal Biotech's strong position across commercial, clinical, and financial areas. He noted the successful global expansion of VYJUVEK, particularly with the upcoming ...

Drug developer Suma Krishnan was 51 when she had the idea for a topical gene therapy to treat a rare and terrible skin disorder, called dystrophic epidermolysis bullosa, in which the skin becomes as ...

Thank you for standing by, and welcome to the Krystal Biotech Q4 2024 Earnings Call. At this time, all participants are on a listen-only mode. After the speakers' presentations, there will be a ...

Not even one year after becoming a commercial biotech, Krystal Biotech has blockbuster dreams for its flagship product. The company launched its topical gene therapy Vyjuvek six months ago and has so ...

Joining me today will be Krish Krishnan, Chairman and Chief Executive Officer, Suma Krishnan, President of Research and Development, Laurent Goux, Senior Vice President and General Manager for Europe, ...

Thank you for standing by and welcome to the Krystal Biotech Third Quarter 2023 Earnings Conference Call. As a reminder today’s conference call is being recorded. I would now like to hand the ...